1. Home
  2. NVCR vs LMAT Comparison

NVCR vs LMAT Comparison

Compare NVCR & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • LMAT
  • Stock Information
  • Founded
  • NVCR 2000
  • LMAT 1983
  • Country
  • NVCR Jersey
  • LMAT United States
  • Employees
  • NVCR N/A
  • LMAT N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • LMAT Medical/Dental Instruments
  • Sector
  • NVCR Health Care
  • LMAT Health Care
  • Exchange
  • NVCR Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • NVCR 1.8B
  • LMAT 2.0B
  • IPO Year
  • NVCR 2015
  • LMAT 2006
  • Fundamental
  • Price
  • NVCR $17.49
  • LMAT $89.08
  • Analyst Decision
  • NVCR Buy
  • LMAT Buy
  • Analyst Count
  • NVCR 5
  • LMAT 6
  • Target Price
  • NVCR $26.60
  • LMAT $92.60
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • LMAT 98.3K
  • Earning Date
  • NVCR 10-30-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • NVCR N/A
  • LMAT 0.72%
  • EPS Growth
  • NVCR N/A
  • LMAT 47.83
  • EPS
  • NVCR N/A
  • LMAT 1.67
  • Revenue
  • NVCR $549,964,000.00
  • LMAT $205,621,000.00
  • Revenue This Year
  • NVCR $16.23
  • LMAT $15.01
  • Revenue Next Year
  • NVCR $6.09
  • LMAT $9.07
  • P/E Ratio
  • NVCR N/A
  • LMAT $54.11
  • Revenue Growth
  • NVCR 8.33
  • LMAT 16.06
  • 52 Week Low
  • NVCR $10.87
  • LMAT $45.96
  • 52 Week High
  • NVCR $24.74
  • LMAT $93.32
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 43.24
  • LMAT 55.00
  • Support Level
  • NVCR $15.61
  • LMAT $84.69
  • Resistance Level
  • NVCR $17.31
  • LMAT $92.84
  • Average True Range (ATR)
  • NVCR 1.29
  • LMAT 2.05
  • MACD
  • NVCR 0.05
  • LMAT -0.07
  • Stochastic Oscillator
  • NVCR 11.59
  • LMAT 75.21

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: